<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137224</url>
  </required_header>
  <id_info>
    <org_study_id>IgPro20_2001</org_study_id>
    <secondary_id>2018-003149-41</secondary_id>
    <nct_id>NCT04137224</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) and IgPro10 (Intravenous Immunoglobulin, Privigen®) in Adults With Systemic Sclerosis (SSc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized, open-label, crossover study to investigate
      the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous
      systemic sclerosis (dcSSc). The pharmacokinetic study aims to evaluate the relative
      bioavailability of IgPro20, and characterize pharmacokinetics of IgPro20 and IgPro10,
      respectively, in subjects with dcSSc. Safety, tolerability, and pharmacokinetics of IgPro10
      will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events (AEs) for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with AEs for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and percentage of subjects with treatment emergent adverse events (TEAEs) for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and percentage of subjects with seriouis adverse events (SAEs) for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and percentage of subjects with adverse events of special interest (AESIs) for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with AEs categorized as infusion site reactions (ISRs) for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with AEs categorized as ISRs for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of ISRs per subject for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of ISRs per infusion for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of ISRs for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of ISRs for IgPro20</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgPro20 relative bioavailability (%F)</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve to the end of the dosing period (AUC0-tau) for IgPro20</measure>
    <time_frame>Up to 240 hours after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve up to the last measurable concentration (AUC0-last) for IgPro20</measure>
    <time_frame>Up to 240 hours after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma drug concentration (Cmax) for IgPro20</measure>
    <time_frame>Up to 240 hours after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma drug concentration (Ctrough) for IgPro20</measure>
    <time_frame>Prior to infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve to the end of the dosing period (AUC0-tau) for IgPro10</measure>
    <time_frame>Up to 672 hours after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve up to the last measurable concentration (AUC0-last) for IgPro10</measure>
    <time_frame>Up to 672 hours after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma drug concentration (Cmax) for IgPro10</measure>
    <time_frame>Up to 672 hours after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma drug concentration (Ctrough) for IgPro10</measure>
    <time_frame>Prior to infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with AEs for IgPro10</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment emergent adverse events (TEAEs) for IgPro10</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with seriouis adverse events (SAEs) for IgPro10</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with adverse events of special interest (AESIs) for IgPro10</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with AEs categorized as ISRs for IgPro10</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>IgPro20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20% liquid formulation of human immunoglobulin for subcutaneous use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgPro10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10% liquid formulation of human immunoglobulin for intravenous use</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IgPro20</intervention_name>
    <description>Human normal immunoglobulin for subcutaneous administration</description>
    <arm_group_label>IgPro20</arm_group_label>
    <other_name>Hizentra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IgPro10</intervention_name>
    <description>Human normal immunoglobulin for intravenous administration</description>
    <arm_group_label>IgPro10</arm_group_label>
    <other_name>Privigen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years (male or female) at time of providing written informed consent

          -  Documented diagnosis of systemic sclerosis (scleroderma) according to American College
             of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria 2013
             (diffuse cutaneous form of SSc).

          -  Modified Rodnan Skin Score (mRSS) ≥ 15 and ≤ 45 at screening

          -  Disease duration ≤ 5 years defined as the time from the first non-Raynaud's phenomenon
             manifestation

          -  Capable of providing written informed consent and willing and able to adhere to all
             protocol requirements

        Exclusion Criteria:

          -  Primary rheumatic autoimmune disease other than dcSSc, including but not limited to
             rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disorder,
             polymyositis, dermatomyositis, as determined by the investigator. Note: Subjects with
             fibromyalgia, secondary Sjogren's syndrome, and scleroderma-associated myopathy at
             screening are not excluded

          -  Subject has mRSS &gt; 2 at the potential subcutaneous (SC) infusion sites

          -  History of skin condition precluding SC infusion, or clinical signs and symptoms of a
             chronic skin disease other than systemic sclerosis or skin manifestation of an
             allergic disease or other dermatological conditions that would interfere with trial
             assessments or compromise safety (eg, dermatitis, eczema, psoriasis)

          -  Subject has clinical signs and symptoms of skin irritation (eg, pruritus, burning,
             erythema) or hypo/ hyperpigmentation (eg, scars, tattoos) at the potential SC infusion
             sites

          -  Significant pulmonary arterial hypertension as documented by mean pulmonary arterial
             pressure &gt; 30 mmHg on right heart catheterization requiring SC or IV prostacyclin or
             use of dual oral therapies

          -  Forced vital capacity &lt; 50% predicted or a diffusing capacity of the lung for carbon
             dioxide (DLCO) ≤ 40% predicted (corrected for hemoglobin)

          -  A female who is pregnant, breastfeeding, or is a woman of childbearing potential who
             does not agree to use acceptable methods of contraception; a male who does agree to
             use acceptable methods of contraception.

          -  Evidence of chronic kidney disease with an estimated glomerular filtration rate (eGFR)
             &lt; 45 mL/min/1.73m2 or if subject is receiving dialysis. Subjects with current
             confirmed diagnosis of diabetes mellitus requiring medication with an eGFR &lt; 90
             ml/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln, innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Josef</name>
      <address>
        <city>Wuppertal</city>
        <zip>42105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of L'Aquila</name>
      <address>
        <city>L'Aquila</city>
        <state>AQ</state>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università Politecnica delle Marche</name>
      <address>
        <city>Ancona</city>
        <zip>60121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Careggi, Rheumatology Unit</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Gaetano Pini</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny W Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Jezus</name>
      <address>
        <city>Warsaw</city>
        <zip>02-008</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Geriatrii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.</ipd_time_frame>
    <ipd_access_criteria>Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

